

## **LABELLING**

## **PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING**

HDPE bottle

### **1. Name of the medicinal product**

[HA703 trade name]\* Lamivudine/tenofovir disoproxil fumarate 300 mg/300 mg tablets

Lamivudine/tenofovir disoproxil fumarate

### **2. Statement of active substance**

Each film-tablet contains 300 mg lamivudine and 300 mg tenofovir disoproxil fumarate (equivalent to 245 mg of tenofovir disoproxil or 136 mg of tenofovir).

### **3. List of excipients**

Contains lactose

### **4. Pharmaceutical form and contents**

Film-coated tablets

30 tablets

### **5. Method and route of administration**

Oral use

Read the patient information leaflet before use.

### **6. Special warning that the medicinal product must be stored out of the reach and sight of children**

Keep this medicine out of the sight and reach of children.

### **7. Other special warning(s), if necessary**

### **8. Expiry date**

EXP {MM/YYYY}

### **9. Special storage conditions**

Do not store above 30°C. Protect from light.

### **10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate**

### **11. Name and address of the supplier**

Lupin Limited  
Kalpataru Inspire  
3rd Floor, Off Western Express Highway

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Lamivudine/tenofovir disoproxil fumarate  
300 mg/300 mg tablets  
(Lupin Limited), HA703

WHOPAR Part 5

November 2024

Santacruz (East), Mumbai  
Maharashtra 400 055  
India

**12. WHO Reference Number (Prequalification Programme)**

HA703

**13. Manufacturer's batch number**

<Batch> <Lot> {number}

**14. (Advice on) General classification for supply**

Medicinal product subject to medical prescription.

**15. Instructions on use**